Detalles de la búsqueda
1.
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
J Neurooncol
; 166(3): 461-469, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38324192
2.
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Oncologist
; 27(1): e76-e84, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305096
3.
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
Int J Cancer
; 148(5): 1183-1191, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32875571
4.
Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in Israel.
Isr Med Assoc J
; 22(12): 788-793, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33381954
5.
Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases.
Breast Cancer Res Treat
; 153(1): 3-8, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26206321
6.
Epidermal Growth Factor Receptor (EGFR) T790M Testing in EGFR-mutated Non-Small Cell Lung Cancer: A Successful Model of Personalized Cancer Care Beyond Resistance.
Isr Med Assoc J
; 21(6): 416-418, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31280514
7.
Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology.
Oncol Rev
; 18: 1355256, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38855534
8.
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.
Front Immunol
; 15: 1364473, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38487531
9.
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
JCO Precis Oncol
; 8: e2300555, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513170
10.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nat Med
; 30(3): 716-729, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38351187
11.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.
J Clin Oncol
; : JCO2400720, 2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38843488
12.
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study.
J Clin Oncol
; : JCO2401001, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857463
13.
Trastuzumab-related cardiac events in the treatment of early breast cancer.
Breast Cancer Res Treat
; 142(1): 1-7, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24154507
14.
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
J Thorac Oncol
; 18(2): 169-180, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36307041
15.
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).
Front Oncol
; 12: 874712, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35646707
16.
Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447.
Cancers (Basel)
; 14(8)2022 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35454955
17.
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
Clin Lung Cancer
; 23(2): 122-134, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35034862
18.
The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study.
J Geriatr Oncol
; 13(8): 1203-1207, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35989184
19.
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
Front Oncol
; 11: 603223, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33777745
20.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Oncoimmunology
; 10(1): 1865653, 2021 01 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33552685